## UNITED STATES SECURITIES AND EXCHANGE COMMISSION May 26, 2017

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

## Amgen Inc.

File No. 0-12477 - CF#35032

Amgen Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on May 8, 2012 and Form 10-K filed on February 19, 2015.

Based on representations by Amgen Inc. that this information qualifies as confidential trade secrets, commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

			Confidential	
<b>Exhibit</b>	to Form	Filed on	<b>Treatment Granted</b>	
10.37	10-K	February 19, 2015	through May 8, 2022	
10.55	10-Q	May 8, 2012	through May 8, 2022	

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary